OncoSec Medical Inc (ONCSQ)

[hschlauch]

Yes, it would be a proof of concept for a platform that could theoretically be an easy plug and play based on biomarkers. The various gene combinations would be virtually limitless, cheaper and easier to produce, safer because the proteins aren't expressed systemically, and more effective when expressed intratumorally. Achieving in-situ vaccination locally allows for an abscopal effect that seeks and destroys distant cancer cells/tumors expressing matching antigens. Systemic anti-PD-1 would still need to be employed due to the exhausted t-cell phenotypes present in mets, but that too could be accomplished through intramuscular electroporation of a plasmid encoding the PD-1 antibody.

We know IL-12 will continue to be the backbone of any multigene product, but imagine if they can demonstrate the successful expression of multiple genes simultaneously and intratumorally. There are probably hundreds of companies, both small and mega cap, designing individual recombinant proteins, to be used mostly in combinations with recombinant checkpoint inhibitors. Oncosec may be able to combine any of these protein targets into a single plasmid product, which would otherwise be highly toxic when delivered systemically as a recombinant protein package.

Oncosec's multigene constructs would be too disruptive to ignore. Next month's presentation is not just about a single new product being tested in mice; it will be more about the proof of concept for a technological innovation that will disrupt the way immunotherapies are administered and produced.